Liposarcoma: Clinical Trials

8 trials for Liposarcoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 terminated. 8 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 28Terminated 8
Phase 12Terminated 2

Follow Liposarcoma: new trials by email Literature Review of Liposarcoma trials Research Report on Liposarcoma

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas
SPH4336 - Liposarcoma, Dedifferentiated
Phase 2TerminatedShanghai Pharma Biotherapeutics USA Inc.142023-08-312025-06-13
TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma
TQB3616 capsule, TQB3616 placebo - Dedifferentiated Liposarcoma
Phase 2TerminatedChia Tai Tianqing Pharmaceutical Group Co., Ltd.262022-08-082025-11-21
ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma
ATX-101 - Leiomyosarcoma, Liposarcoma
Phase 2TerminatedBenjamin Izar42022-01-112023-12-06
A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma
Ontorpacept (TTI-621), Doxorubicin - Leiomyosarcoma
Phase 2TerminatedPfizer762021-06-222024-12-11
Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
Avelumab, Trabectedin - Metastatic Leiomyosarcoma, Metastatic Liposarcoma
Phase 1 / Phase 2TerminatedFred Hutchinson Cancer Center352017-09-282022-04-29
Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)
CMB305, atezolizumab - Sarcoma, Myxoid/Round Cell Liposarcoma
Phase 2TerminatedImmune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)892015-04-292020-07-07
Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial
plitidepsin - Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated Liposarcoma
Phase 2TerminatedInstitut BergoniƩ242012-02-012021-01-25
Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma
nelfinavir mesylate, biopsy, laboratory biomarker analysis - Adult Liposarcoma, Recurrent Adult Soft Tissue Sarcoma
Phase 1 / Phase 2TerminatedCity of Hope Medical Center292006-03-012015-04-01

Narrower conditions

Leiomyosarcoma (3)  ·  Sarcoma (3)  ·  Dermatofibrosarcoma (1)  ·  Hemangiosarcoma (1)  ·  Liposarcoma, Myxoid (1)  ·  Neoplasm Metastasis (1)  ·  Recurrence (1)  ·  Sarcoma, Synovial (1)

Broader conditions

Neoplasms (8)  ·  Neoplasms by Histologic Type (8)  ·  Neoplasms, Adipose Tissue (8)  ·  Neoplasms, Connective and Soft Tissue (8)  ·  Sarcoma (5)  ·  Neoplasms, Muscle Tissue (3)  ·  Neoplasms, Connective Tissue (2)  ·  Disease Attributes (1)  ·  Fibrosarcoma (1)  ·  Neoplasms, Fibrous Tissue (1)  ·  Neoplasms, Vascular Tissue (1)  ·  Neoplastic Processes (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

Biopsy (1)  ·  Blotting, Western (1)  ·  Doxorubicin (1)  ·  Gene Expression Profiling (1)  ·  Immunoenzyme Techniques (1)  ·  Nelfinavir (1)  ·  Reverse Transcriptase Polymerase Chain Reaction (1)  ·  TTI-621 (1)  ·  Trabectedin (1)  ·  atezolizumab (1)  ·  avelumab (1)  ·  plitidepsin (1)

Sponsors

Benjamin Izar (1)  ·  Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1)  ·  City of Hope Medical Center (1)  ·  Fred Hutchinson Cancer Center (1)  ·  Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)  ·  Institut BergoniĆ© (1)  ·  Pfizer (1)  ·  Shanghai Pharma Biotherapeutics USA Inc. (1)

Countries

United States (6)  ·  China (1)  ·  France (1)

Top investigators

Antoine Italiano, MD (1)  ·  Benjamin Izar, MD (1)  ·  Kenneth W Locke, PhD (1)  ·  Seth Pollack (1)  ·  Warren Chow (1)

Results publications

PMID 26041763, PMID 34260265, PMID 39034053

NIH funding

P30CA015704 (1)